NCT07586046RecruitingPhase 2
Defining the Ablative Dose for Y-90 TARE
A Prospective Dose-Escalation Study to Define an Ablative Dose of Yttrium-90 Transarterial Radioembolization Using Advanced Dosimetry and Functional MRI (MARGIN Study)
Source: ClinicalTrials.gov · Last updated 15 Sept 2026
Brief summary (registry, in English)
This study is being done to help doctors improve how they treat liver tumors that cannot be removed by surgery or treated with standard ablation techniques. The researchers want to find out the best amount of radiation that needs to be delivered to completely destroy (or ablate) parts of the liver that have cancer.
- Status (registry)
- Recruiting
- Phase (registry)
- Phase 2
- Study type
- Interventional
- Enrollment
- 30 (estimated)
- First submitted
- 7 May 2026
- Start date
- 15 May 2026
- Primary completion date
- Feb 2029
- Lead sponsor
- Northwestern University
- Diseases
- Liver and biliary tract cancer
- NCT number
- NCT07586046
What you commit to
- Study type: Interventional · Phase 2
- Planned participants: 30
- From 15 May 2026 to the primary completion date, Feb 2029
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other illness
- Known hypersensitivity to gadolinium-based contrast agents.
Age
- Individuals under 18 years of age.
Other
- Extrahepatic metastases.
- Pregnant or breastfeeding individuals.
- Tumors requiring treatment of more than two Couinaud segments.
- Contraindications to MRI (e.g., incompatible pacemakers, claustrophobia unresponsive to sedation).
- Coagulopathy or clinical instability precluding angiographic intervention.
- Prisoners or individuals under legal custody.
- Adults unable to consent.
Who the study is looking for
- Diagnosis of hepatocellular carcinoma (HCC), cholangiocarcinoma, or liver-dominant metastatic disease not amenable to surgical resection or ablation.
- Age ≥18 years.
- Child-Pugh class A or B liver function
- Eastern Cooperative Oncology Group (ECOG) performance status of 0-2.
- Adequate organ and bone marrow function as defined below:
- Leukocytes (WBC) ≥ 3,000/mcL
- Absolute neutrophil count (ANC) ≥ 1,500/mcL
- Hemoglobin ≥ 9 g/dL
- Platelets ≥ 50,000/mcL
- Total bilirubin ≤ 3.0 mg/dL
- AST ≤ 100 U/L, ALT ≤ 120 U/L
- Creatinine ≤ 2.0 mg/dL or estimated GFR ≥ 40 mL/min/1.73 m²
- Ability to undergo imaging and laboratory evaluations required by the study.
- Ability to understand and willingness to sign a written informed consent document.
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Northwestern University Coordinator of this site? Confirm its status | Chicago | United States | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.